Hospital
Prisma Health-Midlands
Prisma Health-Midlands was paid $3.06M by Medicaid between Jan 2018 and Dec 2024, across 137 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 16% of everything it billed.
33Billing provider infoPRISMA HEALTH-MIDLANDS
COLUMBIA, SC 29212
COLUMBIA, SC 29212
33aNPI1538580584assigned 12/18/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.06M
24GClaims200,234
24DCodes billed137
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#57 of 115
Median peer was paid$2.47M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MILLER, POLLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,728 | $596K | |
| 2019 | 29,538 | $569K | |
| 2020 | 23,069 | $441K | |
| 2021 | 25,711 | $324K | |
| 2022 | 30,482 | $379K | |
| 2023 | 31,520 | $383K | |
| 2024incomplete | 32,186 | $365K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 16% | 7,472 | 6,456 | $485K |
| 80048 | Basic metabolic panel (calcium, ionized) | 13% | 6,802 | 5,592 | $386K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 11,321 | 10,343 | $326K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.9% | 2,227 | 2,066 | $181K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.5% | 4,568 | 3,786 | $168K |
| 81001 | 4.5% | 9,910 | 8,682 | $138K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.0% | 2,683 | 2,495 | $122K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.9% | 5,433 | 4,761 | $118K |
| 81025 | 3.5% | 5,677 | 5,129 | $108K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.4% | 3,373 | 2,370 | $104K |
| 36415 | Collection of venous blood by venipuncture | 2.6% | 2,072 | 1,404 | $78K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.4% | 943 | 739 | $75K |
125 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.2% | 912 | $66K |
| 84702 | 2.0% | 2,026 | $60K | |
| 71046 | Radiologic examination, chest; 2 views | 1.9% | 3,174 | $57K |
| 99284 | Emergency room visit (serious) | 1.8% | 9,045 | $55K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 1,895 | $47K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 1,395 | $42K |
| 87081 | 1.3% | 320 | $41K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 2,059 | $35K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.0% | 452 | $31K |
| 87210 | <1% | 656 | $30K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,116 | $24K |
| 86900 | <1% | 342 | $22K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,394 | $21K |
| 99285 | Emergency room visit (most serious) | <1% | 5,177 | $19K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,250 | $18K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,062 | $16K |
| 94010 | <1% | 97 | $15K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 271 | $13K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 898 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,535 | $12K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,581 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,465 | $10K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 24 | $9K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 66 | $6K |
| 86901 | <1% | 405 | $6K | |
| 73560 | <1% | 166 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 425 | $5K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 332 | $5K |
| 87077 | <1% | 316 | $5K | |
| 85027 | <1% | 1,992 | $4K | |
| 73630 | <1% | 84 | $4K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 195 | $4K |
| 86850 | <1% | 56 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 443 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,472 | $3K |
| 76801 | <1% | 663 | $3K | |
| 72100 | <1% | 129 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 31 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,474 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 129 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 64 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 141 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 428 | $2K |
| 76642 | <1% | 53 | $2K | |
| 73610 | <1% | 40 | $2K | |
| 96376 | <1% | 480 | $2K | |
| 93017 | <1% | 66 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 194 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,820 | $1K |
| 81003 | <1% | 471 | $1K | |
| J3490 | Unclassified drugs | <1% | 2,569 | $999.76 |
| 93971 | <1% | 28 | $982.57 | |
| 76000 | <1% | 134 | $938.74 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 25 | $792.39 |
| 73502 | <1% | 26 | $761.93 | |
| 84484 | <1% | 3,492 | $731.10 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 647 | $718.03 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,232 | $611.37 |
| 73130 | <1% | 28 | $597.21 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 245 | $573.98 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,815 | $537.50 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,168 | $537.50 |
| 84703 | <1% | 41 | $488.67 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,094 | $477.14 |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $470.86 |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $465.26 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 526 | $444.10 |
| 86140 | <1% | 135 | $387.37 | |
| 83690 | <1% | 3,578 | $330.91 | |
| 85610 | <1% | 631 | $191.19 | |
| 80061 | Lipid panel | <1% | 60 | $180.35 |
| 74018 | <1% | 13 | $146.94 | |
| 86803 | <1% | 110 | $101.20 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,149 | $74.93 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 399 | $58.68 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 277 | $48.97 |
| 85018 | <1% | 17 | $26.57 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,312 | $22.81 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,727 | $7.93 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 202 | $1.01 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 291 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 441 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 2,295 | $0.00 |
| 94664 | 0% | 229 | $0.00 | |
| 87186 | 0% | 135 | $0.00 | |
| 80076 | 0% | 45 | $0.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 60 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 481 | $0.00 |
| 93976 | 0% | 758 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 62 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 279 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 28 | $0.00 |
| 84145 | 0% | 133 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 29 | $0.00 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 0% | 39 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 56 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 23 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 58 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 15 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,531 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 316 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 254 | $0.00 |
| 83880 | 0% | 358 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,934 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,637 | $0.00 |
| 87040 | 0% | 74 | $0.00 | |
| 83605 | 0% | 619 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 502 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 366 | $0.00 |
| 83735 | 0% | 4,188 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 31 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 382 | $0.00 |
| 85379 | 0% | 353 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 962 | $0.00 |
| 82550 | 0% | 249 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 549 | $0.00 |
| 85730 | 0% | 258 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 352 | $0.00 |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 0% | 105 | $0.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 138 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 62 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 50 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 14 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, POLLY (VP PAYOR STRATEGIES ALIGNMENT)
Parent organizationPRISMA HEALTH-MIDLANDS
| Provider | Location | Paid |
|---|---|---|
| Prisma Health-Midlands | Columbia, SC | $74.58M |
| Prisma Health-Midlands | Columbia, SC | $68.26M |
| Prisma Health-Upstate | Greenville, SC | $25.04M |
| Prisma Health-Upstate | Greenville, SC | $21.98M |
| Prisma Health-Upstate | Greenville, SC | $19.69M |
| Prisma Health-Upstate | Seneca, SC | $15.64M |
| Prisma Health-Midlands | Columbia, SC | $11.77M |
| Prisma Health-Upstate | Greenville, SC | $10.74M |
| Greenville Health Corporation | Greenville, SC | $8.90M |
| Prisma Health-Upstate | Greenville, SC | $8.32M |
| Prisma Health-Upstate | Greenville, SC | $7.45M |
| Prisma Health University Medical Group | Greenville, SC | $7.44M |
| Prisma Health-Midlands | Coulmbia, SC | $7.43M |
| Prisma Health-Midlands | Columbia, SC | $6.88M |
| Prisma Health Tuomey | Sumter, SC | $6.84M |
| Prisma Health-Midlands | Columbia, SC | $6.77M |
| Prisma Health-Upstate | Greenville, SC | $6.37M |
| Prisma Health-Upstate | Greenville, SC | $5.00M |
| Prisma Health-Upstate | Greenville, SC | $4.65M |
| Prisma Health-Midlands | Columbia, SC | $4.63M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.